Targeting CDC42 with CASIN Reprograms Cell Type Specific Transcriptomes and MAPK Driven Transcription Factor Networks in the Aging Brain

Verdict. In our alpha syn mouse model, motor impairment required both alpha syn oligomers and the aging milieu, and pharmacological inhibition of the age hyperactivated Rho GTPase CDC42 with CASIN fully restored motor function, yet the underlying transcriptional pathways mediating this rescue remain to be elucidated. It intersects mitochondrial stress/dysfunction themes (functional impairment; disease context; aging).

What the authors report

Background: Parkinson disease (PD) is driven by alpha synuclein (alpha syn) aggregation and affects vulnerable dopaminergic and GABAergic neurons, and its incidence rises dramatically with age. Brain tissue from one hemisphere (0 to minus 5 mm Bregma) was sequenced using 10x Genomics 3' Chromium, with 3 to 4 mice per condition of both male and female mice.

Key results stated in the abstract include the following. In our alpha syn mouse model, motor impairment required both alpha syn oligomers and the aging milieu, and pharmacological inhibition of the age hyperactivated Rho GTPase CDC42 with CASIN fully restored motor function, yet the underlying transcriptional pathways mediating this rescue remain to be elucidated. Methods We used an inducible alpha syn oligomer PD mouse model across three age groups (6, 16, and 24 months) with four conditions per group: alhpa syn non-induced (OFF), induced (ON), and each with CASIN treatment (OFF CASIN, ON CASIN). Results snRNA-seq demonstrated that CASIN robustly reverted PD related transcriptional alterations at 24 months whereas aging related changes were strongest at 16 months.

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to redox biology, neurobiology, aging, therapeutics. It is relevant to mitochondrial dysfunction discourse because the abstract invokes functional impairment, disease context, aging, neurodegeneration. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. Causal language appears in the abstract; such claims should be treated as provisional until design details (loss-of-function, rescue, dose-response) are verified. Server: biorxiv. Posted 2026-08-13. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

In our alpha syn mouse model, motor impairment required both alpha syn oligomers and the aging milieu, and pharmacological inhibition of the age hyperactivated Rho GTPase CDC42 with CASIN fully restored motor function, yet the underlying transcriptional pathways mediating this rescue remain to be elucidated. Methods We used an inducible alpha syn oligomer PD mouse model across three age groups (6, 16, and 24 months) with four conditions per group: alhpa syn non-induced (OFF), induced (ON), and each with CASIN treatment (OFF CASIN, ON CASIN). Brain tissue from one hemisphere (0 to minus 5 mm Bregma) was sequenced using 10x Genomics 3' Chromium, with 3 to 4 mice per condition of both male and female mice.

Principal findings

1. In our alpha syn mouse model, motor impairment required both alpha syn oligomers and the aging milieu, and pharmacological inhibition of the age hyperactivated Rho GTPase CDC42 with CASIN fully restored motor function, yet the underlying transcriptional pathways mediating this rescue remain to be elucidated.
2. Methods We used an inducible alpha syn oligomer PD mouse model across three age groups (6, 16, and 24 months) with four conditions per group: alhpa syn non-induced (OFF), induced (ON), and each with CASIN treatment (OFF CASIN, ON CASIN).
3. Results snRNA-seq demonstrated that CASIN robustly reverted PD related transcriptional alterations at 24 months whereas aging related changes were strongest at 16 months.
4. Conclusion Convergent gene, transcription factor, pathway, and network level evidence points to EGFR, PI3K, MAPK signaling as the axis through which CASIN may restore mitochondrial and synaptic function in PD and aging

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Comparator/control language is weak or absent in the abstract, limiting causal inference from this brief alone.
• Evidence appears non-human or in vitro from the abstract; translational claims require independent scrutiny.
• Primary source: biorxiv DOI 10.64898/2026.08.07.742974 (posted 2026-08-13).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• Is the mitochondrial phenotype cell-autonomous in neurons/glia, or secondary to systemic/inflammatory signals?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on redox biology, neurobiology, aging, this preprint is worth full-text review if the topic matches your program. Abstract-level takeaway: In our alpha syn mouse model, motor impairment required both alpha syn oligomers and the aging milieu, and pharmacological inhibition of the age hyperactivated Rho GTPase CDC42 with CASIN fully restored motor function, yet the underlying transcriptional pathways mediating this rescue remain to be elucidated. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.